drugset / Trial / NCT00219128

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren 150mg, 300mg, and 600mg to Placebo in Patients With High Blood Pressure.

NCT00219128

Phase 3 Completed 671 enrolled Novartis
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluate the blood pressure lowering effect of aliskiren 150mg, 300mg and 600mg compared to placebo in patients with essential hypertension

Timeline

Start
2004-11
Primary completion
2005-06
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 150 mg
Subject Aliskiren Small molecule 300 mg
Subject Aliskiren Small molecule 600 mg